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Abstract: Recent description of the microbiology of sepsis on the wards or information on the real-life
antibiotic choices used in sepsis is lacking. There is growing concern of the indiscriminate use of
antibiotics and omission of microbiological investigations in the management of septic patients. We
performed a secondary analysis of three annual 24-h point-prevalence studies on the general wards
across all Welsh acute hospitals in years 2016–2018. Data were collected on patient demographics,
as well as radiological, laboratory and microbiological data within 48-h of the study. We screened
19,453 patients over the three 24 h study periods and recruited 1252 patients who fulfilled the entry
criteria. 775 (64.9%) patients were treated with intravenous antibiotics. Only in 33.65% (421/1252)
of all recruited patients did healthcare providers obtain blood cultures; in 25.64% (321/1252) urine
cultures; in 8.63% (108/1252) sputum cultures; in 6.79% (85/1252) wound cultures; in 15.25% (191/1252)
other cultures. Out of the recruited patients, 59.1% (740/1252) fulfilled SEPSIS-3 criteria. Patients
with SEPSIS-3 criteria were significantly more likely to receive antibiotics than the non-septic cohort
(p < 0.0001). In a multivariable regression analysis increase in SOFA score, increased number
of SIRS criteria and the use of the official sepsis screening tool were associated with antibiotic
administration, however obtaining microbiology cultures was not. Our study shows that antibiotics
prescription practice is not accompanied by microbiological investigations. A significant proportion
of sepsis patients are still at risk of not receiving appropriate antibiotics treatment and microbiological
investigations; this may be improved by a more thorough implementation of sepsis screening tools.
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1. Introduction
Sepsis, defined as dysregulated host response leading to life threatening organ dysfunction
secondary to infection, has been thought to contribute significantly to in-hospital mortality [1,2]. Recent
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data suggests that despite increased awareness of this condition, the incidence of sepsis in the last
decade has remained high and its associated morbidity and mortality has increased. This is considered
to be a consequence of ageing populations which are changing cohort characteristics to favour the
admission of patients with lower physiological reserve [3].
The early administration of resuscitation bundles, including appropriate antibiotics, has been
demonstrated to improve patient outcomes [4]. This has led to several national and international
quality improvement initiatives. Such initiatives have been established to facilitate early disease
recognition and rapid initiation of treatment [5,6]. In response to sepsis in England and Wales, the
NHS has adopted a standardised sepsis screening tool and Sepsis-Six bundle [7]. We have investigated
the effectiveness of this approach previously in our series of point prevalence studies [8–10].
Despite the evidence of the potential benefit of these initiatives, there is growing concern
surrounding the indiscriminate use of antibiotics and omission of microbiological investigations in
patient management [11–13]. Additionally, there is no recent description of the microbiology of sepsis
on the wards or information on the real-life antibiotic choices used in sepsis.
In light of these controversies, the primary objective of the study was to investigate antibiotic
prescribing practices on general wards and emergency departments (ED) in at-risk population of
patients in acute hospitals in Wales. The secondary objective was analysis of outcomes of microbiological
investigations of sepsis patients using our comprehensive database.
2. Experimental Section
2.1. Study Design and Participants
Secondary analysis of patient episodes was performed on the patient population recruited into
three annual 24-h point-prevalence studies on the general wards and ED across all Welsh acute hospitals
in the years 2016, 2017 and 2018. In order to be entered into the study, each hospital was required to
have a 24/7 consultant supervised ED and the ability to admit and treat any acutely unwell patient. We
recruited patients with National Early Warning Score (NEWS) ≥3 and proven or suspected infection
documented in the clinical notes. Those who were under 18, in mental health or critical care units were
excluded as these patients are not covered by the NEWS system in the Welsh hospitals.
Data were collected using a digital platform, the methodology and performance of which is
described in detail in our previous studies [8,14]. The data were collected from medical and nursing
records and comprised of patient demographics, baseline pre-admission characteristics, clinical
observations, as well as radiological, laboratory and microbiological data within 48-h of the study.
The completion of sepsis screening tools, sepsis care bundles and antibiotic treatment were also
recorded. Follow-up data collection was continued up until 90 days post-study.
Ethical approval was given by the South Wales Regional Ethics Committee (16/WA/0071). Written
informed consent was gained from each patient, or by proxy for those who lacked capacity. The trial
was registered prospectively at www.isrctn.com (ISRCTN86502304).
2.2. Statistical Analysis
Categorical variables are described as proportions and are compared using the Chi-square test.
Continuous variables are described as median and inter-quartile range. A two-tailed p-value < 0.05
was considered statistically significant. To identify factors associated with antibiotic administration
we performed a multivariable logistic regression analysis with backwards elimination method, using
antibiotic administration as a dependent variable. The likelihood ratio test was used in the backward
elimination method using a significance level of p-value < 0.05. We only considered the main effects in
this analysis; interaction terms were not included in the model. We determined the goodness-of-fit of
the model using the Hosmer–Lemeshow test. The results of the multivariable analysis are shown as
odds ratios (OR) and 95% confidence interval (95% CI). All statistical tests were calculated using SPSS
25.0 (SPSS Inc., Chicago, IL, USA).
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3. Results
3.1. Patient Characteristics
We screened 19,453 patients over three 24-h point-prevalence study periods in 14 acute hospitals
in Wales in 2016, 2017 and 2018. We recruited 1252 patients who fulfilled the study criteria. Patient
characteristics are summarised in Table 1, with a more detailed comparison of the patients recruited
in the ED and the ward provided in Supplementary Table S1. We had information about the use of
antibiotics for 1195 patients.
Table 1. Patient demographics information.
Median Interquartile Range (Q3–Q1)
Age (years) 73 22
Number of co-morbidities (n) 1 2
Frailty Score 5 3
NEWS score 4 3
SIRS score 2 2
SOFA score 2 2
Number of Patients, n (%)
Sex, male 624 (49.8)
SEPSIS-3 criteria present 740 (59.1)
ED admission 193 (15.4)
General medical admission 544 (43.5)
General surgical admission 197 (15.7)
Admission to other ward 321 (25.6)
Ceiling of care documented 263 (21.0)
DNA-CPR documented 305 (24.4)
COPD 347 (27.7)
Diabetes 262 (20.9)
Heart failure 144 (11.5)
Hypertension 417 (33.3)
Ischaemic heart disease 210 (16.8)
Liver disease 43 (3.4)
Neuromuscular disease 40 (3.2)
Recent chemotherapy 50 (4.0)
Chronic antibiotics 94 (7.5)
NEWS, National Early Warning Score; SIRS, Systemic Inflammatory Response Syndrome; SOFA, Sequential Organ
Failure Assessment; ED, Emergency Department; DNA-CPR, do not attempt cardio-pulmonary resuscitation; COPD,
Chronic Obstructive Pulmonary Disease.
3.2. Antibiotics Characteristics
Out of 1,195 patients, 775 (64.9%) were treated with intravenous (IV) antibiotics. Majority of
patients were treated with one IV antibiotic (median 1, range 0–5). The antibiotics used were broad
spectrum, with Piperacillin/Tazobactam (Tazocin) being the most commonly prescribed (40.5% of
patients treated with antibiotics, 314/775). The most frequently prescribed antibiotics are presented in
Figure 1. Tazocin was more commonly used as a monotherapy, however, in a significant proportion of
patients, it was used in addition to other antibiotics (32.1%, 101/314). Tazocin was most commonly
used in combination with Metronidazole and Clarithromycin (19/101 and 16/101, respectively).
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Figure 1. The most frequently prescribed antibiotics. Bars represent the number of times each antibiotic
was prescribed.
3.3. Organism Characteristics
The vast majority of patients did not undergo microbiological investigations. Only in 33.65%
(421/1252) of all recruited patients did healthcare providers obtain blood cultures; in 25.64% (321/1252)
urine cultures; in 8.63% (108/1252) sputum cultures; in 6.79% (85/1252) wound cultures; and in 15.25%
(191/1252) other cultures. The yield of the cultures was very low with positive result in only 13.06%
(55/421) blood cultures, 13.71% (44/321) urine cultures, 45.37% (49/108) sputum cultures, 32.94%
(28/85) wound cultures and 8.90% (17/191) other cultures. The most commonly identified organism
in blood cultures was E. coli (17 out of 421 cultures) and Gram-positive cocci (16 out of 421 cultures),
the latter most commonly interpreted as contamination. None of the organisms were characterized as
multi-resistant. Detailed microbiological results are presented in Table 2.
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Table 2. Organisms identified by microbiological investigations.
Blood Culture (n) Sputum Culture (n) Urine Culture (n) Wound Culture (n) Other Culture (n)
Escherichia coli (17) Respiratory flora (33) Escherichia coli (33) Mixed growth (27) MRSA (4)
Gram positive cocci (16) Haemophilus influenzae (11) Mixed growth (18) Staphylococcus aureus (16) Aspergillus (2)
Coagulase negative Staphylococcus (6) Candida albicans (9) KESC group (3) Coliform (2) Escherichia coli (2)
MSSA (6) Pseudomonas aeruginosa (9) Contamination (2) Serratia marcescens (2) Rhinovirus (2)
Pseudomonas aeruginosa (6) Mixed growth (8) Enterococcus bacteria (2) Skin flora (2) Aggregatibacter aphrophilus (1)
Streptococcus pneumoniae (5) Moraxella catarrhalis (3) Pseudomonas aeruginosa (2) Candida albicans (1) Clostridium difficile (1)
Klebsiella pneumoniae (3) Staphylococcus aureus (3) Proteus mirabilis (1) Enterococcus (1) Enterovirus (1)
Gram negative bacilli (2) Streptococcus pneumoniae (2) Yeast (1) Escherichia coli (1) Staphylococcus aureus (1)
MRSA (2) Corynebacterium striatum (1)
No growth (259)
Group B Streptococcus (1) Streptococcus intermedius (1)
Proteus mirabilis (2) Escherichia coli (1) Pseudomonas aeruginosa (1) Yeast (1)
Staphylococcus aureus (2) Klebsiella pneumoniae (1) Streptococcus viridans (1)
No growth (175)













The organisms are listed from the most to least frequently detected by each culture type.
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3.4. Antibiotics Use in Patients Fulfilling SEPSIS-3 Criteria
Out of the recruited patients, 59.1% (740/1252) fulfilled SEPSIS-3 criteria of Sequential Organ
Failure Assessment (SOFA) score of two or above. Patients with SEPSIS-3 criteria were significantly
more likely to receive antibiotics than the non-septic cohort (490/740 of septic patients received
antibiotics in comparison to 285/512 non-septic patients p < 0.0001) (Figure 2). Nevertheless, 33.78%
(250/740) of patients fulfilling SEPSIS-3 criteria did not receive any antibiotics. The vast majority of this
cohort of patients had no microbiological investigations done. Only 24.8% (62/250) had blood cultures,
10% (25/250) sputum cultures, 23.2% (58/250) urine cultures, 6.8% (17/250) wound cultures and 14.4%
(36/250) other cultures. These results are similar for other sepsis screening tools, such as Systemic
Inflammatory Response Syndrome (SIRS), quick SOFA (qSOFA) and Red Flag Sepsis (data not shown).
Figure 2. Comparison between antibiotics use between patients fulfilling SEPSIS-3 criteria (septic) and
patients not fulfilling SEPSIS-3 criteria (non-septic). Septic patients were significantly more likely to
receive antibiotics than the non-septic cohort p < 0.0001.
3.5. Antibiotics and Microbiological Investigations
Analysing only patients who received antibiotics, we found that 49.75% (300/603) had blood
cultures, 13.81% (70/507) had sputum cultures, 35.47% (210/592) had urine cultures, 9.01% (53/588)
had wound cultures and 13.42% (104/775) had other microbiological investigations. We also found
that patients who received antibiotics were more likely to have obtained blood and urine cultures
in comparison to the patients with no antibiotic treatment (p < 0.0001 and p = 0.04, respectively).
No significant difference in sputum, wound or other microbiological investigations was noticed for
this cohort. On the other hand, a significant proportion of patient who underwent investigations
did not receive antibiotics. We found that 28.74% (121/421) of patients with blood, 35.19% (38/108)
sputum, 34.65% (111/321) urine and 40.57% (71/175) other cultures were not prescribed any antibiotics.
Further details on how the presumed site of infection influenced antibiotic therapy and microbiology
investigations is provided in Supplementary Table S2.
We also investigated whether the use of official screening tools had an impact on antibiotic
prescription practice. We found that the screening tools have been completed for only 17.7% (221/1252)
of patients, despite high NEWS score and documented suspicion of infection. Interestingly, the screened
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patients were significantly more likely to receive antibiotics in comparison to non-screened patients
(p < 0.0001) and to have blood culture (p = 0.001) but no other microbiological investigations.
3.6. Factors Influencing Antibiotics Administration
We used a binary logistic regression model to independently assess variables that in a univariate
analysis were associated with antibiotic use and we felt were clinically important. Consequently, we
included frailty score, SOFA score, number of SIRS criteria present, any cultures obtained and official
screening tool completed. Hosmer–Lemeshow test indicated a good model fit. Increase in SOFA score
(OR 1.078; 95% CI 1.008–1.152), increased number of SIRS criteria present (OR 1.225; 95% CI 1.080–1.389)
and completion of the official screening tool (OR 2.949; 95% CI 1.996–4.358) were independently
associated with antibiotic administration, however increased frailty score or microbiological sample
collection was not.
4. Discussion
Our study shows that antibiotic prescription practice for patients with suspected sepsis is not
accompanied by microbiological investigations. The majority of recruited patients with suspicion
or confirmed infection, did not undergo microbiological investigations and were prescribed broad
spectrum antibiotics.
Our study highlights the current practices of antibiotics prescribing in an era when awareness
of sepsis is raised and in a healthcare system which has adopted a nation-wide screening tool and
escalation process for the condition [7]. Patient characteristics, demographics and co-morbidities were
similar to recently published large scale retrospective analyses and multi-national studies of similar
methodology [4,15,16]. Antibiotic administration was common in this at-risk population, similarly to
the IMPRESS study, however other elements of the Sepsis-Six bundle or the 3-h sepsis bundle appeared
to be lacking [4,5,17]. In line with previous results of large quality improvement initiatives, the use of a
checklist-based screening tool was associated with better adherence to microbiology sampling and
antibiotic administration guidance [6].
The implementation of the sepsis bundles both within the UK and internationally have highlighted
a potential drawback of the “treat first, ask questions later” approach, which fails to take into account
the several factors which could influence the bedside clinicians, resulting in less than ideal practice [4,6].
First, the diagnosis of sepsis is notoriously difficult with limited clinical and laboratory information
available. In our previous work using the same patient population, we have shown that the different
clinical screening criteria commonly used outside of the critical care units capture different patient
populations and that combining the SOFA- and SIRS-based approaches would identify around 80% of
the patients at high risk of death [10]. Our findings that both SIRS and SOFA scores were independently
associated with antibiotic administration are encouraging and could highlight a potential way forward
for everyday clinical practice. Second, antibiotic use can have significant adverse consequences, from
anaphylaxis, as highlighted recently by the NAP6 findings in the UK, to unnecessary exposure to
antibiotics if a patient does not have a bacterial infection, or the treatment is continued beyond the
clinically indicated duration [18,19]. Our findings, that broad spectrum antibiotic use was common
without appropriate microbiological investigations is alarming, especially as it is corroborated by
international data [4,20]. It has been shown, that patients with septic shock would benefit from
early administration of broad-spectrum antibiotics, however convincing data on the less severe sepsis
population is lacking [6,15,17]. In a recent randomised controlled trial of community-acquired sepsis
with very similar patient population characteristics to our study, early (within 1-h of recognition)
broad spectrum antibiotic administration failed to improve clinical outcomes compared to the usual
care group which received antibiotics after assessment in the ED [21]. We have shown, that severe
infection leading to organ dysfunction per se is relatively rarely attributable to death in the same
patient population [22]. This finding was echoed in a recent study from the US, where Rhee et al.
found that although sepsis was present in 52% of terminal hospitalisations, underlying causes of death
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were related to severe chronic comorbidities and most sepsis-associated deaths were unlikely to be
preventable through better hospital-based care [23].
Early identification of the infectious organism could allow more targeted and effective treatment.
This could also facilitate the use of antibiotics with narrower spectra or early antibiotics switching
instead of using broad-spectrum antibiotics, an approach advocated in sepsis for over a decade [24,25].
Clinically, the nature of the organism triggering sepsis appears to have considerable prognostic
significance on the ICU [26–28]. It can have an impact on clinical presentation as well as sepsis
morbidity and mortality. Moreover, the nature of the infection can determine the mechanism of host
response both to the pathogen and initiated therapy [29]. Targeted antimicrobial therapy would reduce
the risk of development of multidrug-resistant organisms as well as antibiotics-related infections
such as Clostridium difficile diarrhoea [30]. In a previous report, we found that over 98% of organisms
responsible for positive blood cultures are sensitive to the combination of Tazocin and Gentamicin [31].
This might explain the preferential use of Tazocin in our current sample. However, in the same report
it has been emphasised that before antibiotic administration, appropriate microbiology cultures should
be obtained, which has not happened in the majority of our cases [31].
The lack of microbiological investigations could be influenced by the low yield of detection
of organisms of the gold standard” microbiological investigations. In our study, the yield of blood
cultures, which are a part of Sepsis Six bundle, was only 13.06%, similar to other reports [15,30,32].
This confirms the need to develop more sensitive diagnostic microbiological investigations. Emerging
technologies such as next-generation sequencing, PCR-Electrospray Ionization mass spectrometry or
use of various ‘-omics’ techniques [30] might change the approach to current microbiology standards
and improve the detection of organisms in the future.
The strengths of our study include the participation of centres all across Wales, including both
academic and general district hospitals, as well as using prospective data collection methods, resulting
in a clinically rich and complete dataset.
Our study has some limitations. Firstly, patients with sepsis who had NEWS below 3 could have
been missed and not recruited into our study [33,34]. However, recent data suggest that outside of the
intensive care setting, the NEWS cut-off of 3 may be the most optimal trigger for sepsis screening [35].
Secondly, due to the 24-h point-prevalence character of our study we were not able to obtain information
on how long the broad-spectrum antibiotics we used for in-patients’ treatment and whether an optimal
step-down management was implemented. Lastly, due to the prospective nature of the study, the
data collector could have possibly been recruiting patients before their team undertook investigations
and management steps, especially during the night shift. However, we collected the microbiology
results retrospectively and also reviewed the prescription charts where they were available to minimise
this bias.
5. Conclusions
In conclusion, a significant proportion of sepsis patients are still at risk of not receiving appropriate
antibiotics treatment and microbiological investigations. This could be improved by a more thorough
implementation of sepsis screening tools. In addition, adopting both SIRS and SOFA clinical criteria
may help to identify the high-risk population, where microbiological investigations should accompany
appropriate antimicrobial therapy.
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administration and microbiology investigations by infection source.
Author Contributions: Conceptualization, M.K., B.S. and T.S.; data curation, T.S.; formal analysis, M.K. and T.S.;
funding acquisition, T.S.; investigation, H.U., J.L., A.F., C.Z., S.C., S.K., T.C., E.A., E.M., U.A., B.P., J.N., A.W., A.O.,
Z.X.T., R.R., J.W., Y.A., V.U., F.H., J.S., S.G., H.P., J.I., C.G., N.D., A.K., T.G., P.M. and A.S.; methodology, M.K., B.S.
and T.S.; project administration, T.S.; resources, T.S.; software, B.S.; validation, M.K., B.S. and T.S.; visualization,
M.K.; writing—original draft, M.K. and T.S.; writing—review and editing, M.K., B.S., H.U., J.L., A.F., C.Z., S.C.,
J. Clin. Med. 2019, 8, 1337 9 of 11
S.K., T.C., E.A., E.M., U.A., B.P., J.N., A.W., A.O., Z.X.T., R.R., J.W., Y.A., V.U., F.H., J.S., S.G., H.P., J.I., C.G., N.D.,
A.K., T.G., P.M., A.S. and T.S.
Funding: This research was funded by Fiona Elizabeth Agnew Trust: Features Award 2016 and Welsh Intensive
Care Society Research Award 2015. The APC was funded by Cardiff University.
Acknowledgments: Welsh Digital Data Collection Platform Collaborators: Richard Pugh, Peter Havalda,
Ceri Battle, Harsha Reddy, Maria Hobrok, Igor Otahal, Vincent Hamlyn, Luis Macchiavello, Rhidian
Jones, Orsolya Minik, Paul Morgan, Gemma Ellis, Ceri Brown, Chris Littler, Chris Subbe, Judith E Hall,
Katherine Carnegie, Helena Colling-Sylvester, Natasha Logier, Lara Wirt, Georgina St Pier, Richard Betts,
Kyriaki Mitsaki, Mari Tachweed Pierce, Sioned Davies, Yakeen Hafouda, Jessica Pearce, Erin Ifan,
Grace Lacey, Francesca Mitchell, Timothy Spence, Angharad Evans, Sarah Hardie, Harriet Seymour, Sam Willis,
Matthew Warlow, Shanali Thanthilla, Thomas Downs, Nina Foley, Chad McKeown, Liam Sharma, Tom Pontin,
Emma Shore, Tamara Hughes, Sam Nightingale, Philby Baby, Matthew Shield, Alice Cross, Jenna Boss, Olivia Ross,
George Ashton, Kimaya Pandit, Daniel Davies, Cameron Garbutt, Charlotte Johnston, Marcus Cox, Megan Stone,
Victoria Maidman, Katherine Godfray, Rhidian Caradine, Hannah Beetham, Adanna Nicole Anomneze-Collins,
Jeanette Tan, Yasmina Abdelrazik, Azizah Khan, Isabella Patterson, Nabihah Malik, Aidan Clack, Lewis Oliva,
Tyler Thomas, Charlotte Pickwick, Jorge Carter, Fiona Andrew, Naseera Seedat, Roshni Patel, Megan Walker,
Alicia Boam, Jessica Randall, Beth Bowyer, Josh Edwards, Natasha Jones, Mathoorika Sivananthan, Emily Ireland,
Emma Walker, Yusuf Cheema, Kevin Pinto, Eleanor Hartley, Oscar Emanuel, Rhiannon Long, Megan Selby,
Abigail Hodgson, Elilis Wardle, Alexandra Urquhart, Jack Barrington, Matthew Ashman, Elizabeth Adcock,
Amelia Dickinson, Rebecca Jordache, Rym Chafai El Alaoui, Timia Raven-Gregg, Tom Liddell-Lowe, Caitlin Ong,
Harriet Reed, Frederika Alice St John, Weronika Julia Kozuch, Isabelle Ray, Ffion Bennett, Irukshi Anuprabha
Silva, Sin Ting Natalie Cheng, Umme-Laila Ali, Noreena Syed, Luke Murphy, Humaira Hussain, Joanna Hawkins,
Molly Timlin, Zeid Atiyah, Rebecca Creamer, Maham Zafar, Ahmad Almazeedi, Hannah Brunnock, Zain Nasser,
Mekha Jeyanthi, Poorya Moghbel, Katie Kwan, Isobel Sutherland, Frank Davis, Lucas Wilcock, Rachel Evans,
Rhys Jones, Sung Yeon Kwak Lily Farakish, Holly Rhys-Ellis, Amelia Stoddart, Kate Moss, Tallulah Ray, Tessa
David, Talea Roberts, Annie Quy, Aniket Paranjape, Felicity Bee, Nutchanun Poolworaluk, Mary Keast, Si Liang
Yao, Dion Manning, Isobel Irwin, Mariana Nalbanti, Raven Joseph, Jack Tagg, David Purchase, Pan Myat, Ayako
Niina, Tyler Joshua Jones, Lowri Hughes Thomas, Natalie Hoyle, Patrick Benc, Ellen Davies, Meng-Chieh Wu,
David Fellows, Sam Tilley, Anastasia Donnir, Gaautham Ravishangar, Emanuela Howard, Charlotte Salmon,
Vanessa Yeo Yung Ling, Kimiya Asjadi, Carven Chin Yee Shean, Zoe McCarroll, Oritseweyimi Amatotsero, Hei
Man Priscilla Chan, John Ng Cho Hui, Antonia Ashaye, Josephine Acheampong, Ayowade Adeleye, Saber Ahmed,
Alexandra Chrysostomou, Luthfun Nessa, Aalaa Fadlalla, Rhian Morgan, Georgia Parry, Elizabeth Hodges,
Amelia Heal, Chloe Scott, Alice Tayler. Meshari Alsaeed, Hannah Williams, Arfa Ayob, Nor Farzana, Sweta
Parida, David Lawson, Michal Mazur, Lezia D’Souza, Bethan Ponting, Terrance Lau, Ruairidh Kerrigan, Lucy
Morgan, Roshan Vindla, Becky James, Amirah Amin Ariff, Wan Binti Wan Azzlan, Charlotte Collins, Elizabeth
Wickens, Alisa Norbee, Aliya Zulkefli, Thomas Haddock, Megan Thomas, Matthew Lee, Akshita Dandawate,
Holleh Shayan-Arani, Ellie Taylor, Oliver Kyriakides, Rachel Price, Ffion Haf Mackey, Emily Haines, Samuel Chun,
Chantal Roberts, Laura Heekin, Kathy Wang, Rhianna Church, Shrina Patel, Marianne Broderick, Hannah Whillis,
Daniel Craig Hathaway, Emel Yildirim, Caitlin Atkins, Adam George Mounce, Anoopama Ramjeeawon, Ndaba
Mtunzi, Duncan Soppitt, Jay Hale, Jack Wellington, Danielle Lis, Sophie Stovold, Sam Vickery, Nia Jones, Alice
O’Donnell, Monty Cuthbert, Osa Eghosa, Muhammad Karim, Lowri Williams, Louise Tucker, Ailsa MacNaught,
Swagath Balachandran, Abbie Shipley, Jennifer Louise Kent, Samuel Tilley, Bethany Davies, Emma Withers,
Krishna Parmar, Lucie Webber, Harry Smith, Rachel Watson, Natalie Hoyle, Rym Chafai El Alaoui, Omar Marei,
Emma Kirby, Anna Gilfedder, Lydia Maw, Sarah O’Connor, Abigail Rogers, Clare Chantrill, Amal Robertson,
Jonathan Foulkes, Rahana Khanam, Jomcy John, Isobel Sutherland, Sarah Hannah Meehan, Huria Metezai, Hannah
Dawson, Eloise Baxendale, Karishma Khan, Pan Myat, Oliver Moore, Hse Juinn Lim, Nima-banu Allybocus,
Maneha Sethi, Emelia Boggon, Ibrahim Alkurd, Genevieve Lawrence, Jade Brown, Lowri Hughes Thomas, Emily
Murphy, Evie Lambert, Jeremy Guilford, Mariam Almulaifi, Arwel Poacher, Sara Tanatova, Jasmine Kew, Megan
Eilis Clark, Ellen Hannay, Olesya Godsafe, Christina Houghton, Francesca Lavric, Rachel Mallinson, Niamh
McSwiney, Yin Yin Lim, Zong Xuan Lee, Nur Zulkifli, Sheryl Lim, Lim Xin, Abduahad Taufik, James Cochrane,
Samuel Willis, Sieh Yen Heng, Alex Cooper, Henrik Graf von der Pahlen, Isabella Talbot, Robin Gwyn Roberts,
Aisling Sweeney and Cerian Roberts
Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the
study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to
publish the results.
References
1. Singer, M.; Deutschman, C.S.; Seymour, C.W.; Shankar-Hari, M.; Annane, D.; Bauer, M.; Bellomo, R.;
Bernard, G.R.; Chiche, J.D.; Coopersmith, C.M.; et al. The Third International Consensus Definitions for
Sepsis and Septic Shock (Sepsis-3). JAMA 2016, 315, 801–810. [CrossRef] [PubMed]
J. Clin. Med. 2019, 8, 1337 10 of 11
2. Sakr, Y.; Jaschinski, U.; Wittebole, X.; Szakmany, T.; Lipman, J.; Ñamendys-Silva, S.A.; Martin-Loeches, I.;
Leone, M.; Lupu, M.N.; Vincent, J.L.; et al. Sepsis in Intensive Care Unit Patients: Worldwide Data from the
Intensive Care over Nations Audit. Open Forum Infectious Diseases 2018, 5, ofy313. [CrossRef] [PubMed]
3. Vincent, J.L.; Lefrant, J.Y.; Kotfis, K.; Nanchal, R.; Martin-Loeches, I.; Wittebole, X.; Sakka, S.G.; Pickkers, P.;
Moreno, R.; Sakr, Y. Comparison of European ICU patients in 2012 (ICON) versus 2002 (SOAP). Intensive
Care Med. 2018, 44, 337–344. [CrossRef] [PubMed]
4. Rhodes, A.; Phillips, G.; Beale, R.; Cecconi, M.; Chiche, J.D.; De Backer, D.; Divatia, J.; Du, B.; Evans, L.;
Ferrer, R.; et al. The Surviving Sepsis Campaign bundles and outcome: Results from the International
Multicentre Prevalence Study on Sepsis (the IMPreSS study). Intensive Care Med. 2015, 41, 1620–1628.
[CrossRef] [PubMed]
5. Daniels, R.; Nutbeam, T.; McNamara, G.; Galvin, C. The sepsis six and the severe sepsis resuscitation bundle:
A prospective observational cohort study. Emerg. Med. J. 2011, 28, 507. [CrossRef]
6. Levy, M.M.; Rhodes, A.; Phillips, G.S.; Townsend, S.R.; Schorr, C.A.; Beale, R.; Osborn, T.; Lemeshow, S.;
Chiche, J.D.; Artigas, A.; et al. Surviving Sepsis Campaign: Association Between Performance Metrics and
Outcomes in a 7.5-Year Study. Crit. Care Med. 2015, 43, 3–12.
7. Hancock, C. A national quality improvement initiative for reducing harm and death from sepsis in Wales.
Int. Crit. Care Nurs. 2015, 31, 100–105. [CrossRef] [PubMed]
8. Szakmany, T.; Lundin, R.M.; Sharif, B.; Ellis, G.; Morgan, P.; Kopczynska, M.; Dhadda, A.; Mann, C.;
Donoghue, D.; Rollason, S.; et al. Sepsis Prevalence and Outcome on the General Wards and Emergency
Departments in Wales: Results of a Multi-Centre, Observational, Point Prevalence Study. PLoS ONE 2016, 11,
e0167230. [CrossRef]
9. Szakmany, T.; Pugh, R.; Kopczynska, M.; Lundin, R.M.; Sharif, B.; Morgan, P.; Ellis, G.; Abreu, J.;
Kulikouskaya, S.; Bashir, K.; et al. Defining sepsis on the wards: Results of a multi-centre point-prevalence
study comparing two sepsis definitions. Anaesthesia 2018, 73, 195–204. [CrossRef]
10. Kopczynska, M.; Sharif, B.; Cleaver, S.; Spencer, N.; Kurani, A.; Lee, C.; Davis, J.; Durie, C.; Joseph-Gubral, J.;
Sharma, A.; et al. Red-flag sepsis and SOFA identifies different patient population at risk of sepsis-related
deaths on the general ward. Medicine 2018, 97, e13238. [CrossRef]
11. Burke, J.; Wood, S.; Hermon, A.; Szakmany, T. Improving outcome of sepsis on the ward: Introducing the
‘Sepsis Six’ bundle. Nurs. Crit. Care. 2019, 24, 33–39. [CrossRef]
12. Marik, P.E.; Malbrain, M.L.N.G. The SEP-1 quality mandate may be harmful: How to drown a patient with
30 mL per kg fluid! Anaesthesiol. Intensive Ther. 2017, 49, 323–328. [CrossRef] [PubMed]
13. Perner, A.; Singer, M. Fixed minimum fluid volume for resuscitation: Con. Intensive Care Med. 2017, 43,
1681–1682. [CrossRef] [PubMed]
14. Sharif, B.; Lundin, R.M.; Morgan, P.; Hall, J.E.; Dhadda, A.; Mann, C.; Donoghue, D.; Brownlow, E.; Hill, F.;
Carr, G.; et al. Developing a digital data collection platform to measure the prevalence of sepsis in Wales. J.
Am. Med. Inf. Assoc. 2016, 23, 1185. [CrossRef] [PubMed]
15. Seymour, C.W.; Gesten, F.; Prescott, H.C.; Friedrich, M.E.; Iwashyna, T.J.; Phillips, G.S.; Lemeshow, S.;
Osborn, T.; Terry, K.M.; Levy, M.M. Time to Treatment and Mortality during Mandated Emergency Care for
Sepsis. NEJM 2017, 376, 2235–2244. [CrossRef] [PubMed]
16. Liu, V.X.; Fielding-Singh, V.; Greene, J.D.; Baker, J.M.; Iwashyna, T.J.; Bhattacharya, J.; Escobar, G.J. The
Timing of Early Antibiotics and Hospital Mortality in Sepsis. Am. J. Respir. Crit. Care Med. 2017, 196, 856–863.
[CrossRef] [PubMed]
17. Rhodes, A.; Evans, L.E.; Alhazzani, W.; Levy, M.M.; Antonelli, M.; Ferrer, R.; Kumar, A.; Sevransky, J.E.;
Sprung, C.L.; Nunnally, M.E.; et al. Surviving Sepsis Campaign: International Guidelines for Management
of Sepsis and Septic Shock: 2016. Intensive Care Med. 2017, 43, 304–377. [CrossRef] [PubMed]
18. Harper, N.J.; Cook, T.M.; Garcez, T.; Farmer, L.; Floss, K.; Marinho, S.; Torevell, H.; Warner, A.; Ferguson, K.;
Hitchman, J.; et al. Anaesthesia, surgery, and life-threatening allergic reactions: Epidemiology and clinical
features of perioperative anaphylaxis in the 6th National Audit Project (NAP6). Br. J. Anaesth. 2018, 121,
159–171. [CrossRef]
19. Klompas, M.; Calandra, T.; Singer, M. Antibiotics for Sepsis—Finding the Equilibrium. JAMA 2018, 320,
1433–1434. [CrossRef]
J. Clin. Med. 2019, 8, 1337 11 of 11
20. Bloos, F.; Rüddel, H.; Thomas-Rüddel, D.; Schwarzkopf, D.; Pausch, C.; Harbarth, S.; Schreiber, T.;
Gründling, M.; Marshall, J.; Simon, P.; et al. Effect of a multifaceted educational intervention for anti-infectious
measures on sepsis mortality: A cluster randomized trial. Intensive Care Med. 2017, 43, 1602–1612. [CrossRef]
21. Alam, N.; Oskam, E.; Stassen, P.M.; van Exter, P.; van de Ven, P.M.; Haak, H.R.; Holleman, F.; van Zanten, A.;
van Leeuwen-Nguyen, H.; Bon, V.; et al. Prehospital antibiotics in the ambulance for sepsis: A multicentre,
open label, randomised trial. Lancet Respir. Med. 2018, 6, 40–50. [CrossRef]
22. Kopczynska, M.; Sharif, B.; Cleaver, S.; Spencer, N.; Kurani, A.; Lee, C.; Davis, J.; Durie, C.; Joseph-Gubral, J.;
Sharma, A.; et al. Sepsis-related deaths in the at-risk population on the wards: Attributable fraction of
mortality in a large point-prevalence study. BMC Res. Notes 2018, 11, 720. [CrossRef] [PubMed]
23. Rhee, C.; Jones, T.M.; Hamad, Y.; Pande, A.; Varon, J.; O’Brien, C.; Anderson, D.J.; Warren, D.K.; Dantes, R.B.;
Epstein, L.; et al. Prevalence, Underlying Causes, and Preventability of Sepsis-Associated Mortality in US
Acute Care Hospitals. JAMA Netw. Open 2019, 2, e187571. [CrossRef] [PubMed]
24. Septimus, E.J.; Coopersmith, C.M.; Whittle, J.; Hale, C.P.; Fishman, N.O.; Kim, T.J. Sepsis National Hospital
Inpatient Quality Measure (SEP-1): Multistakeholder Work Group Recommendations for Appropriate
Antibiotics for the Treatment of Sepsis. Clin. Infect. Dis. 2017, 65, 1565–1569. [CrossRef] [PubMed]
25. Levy, M.M.; Evans, L.E.; Rhodes, A. The Surviving Sepsis Campaign Bundle: 2018 update. Intensive Care
Med. 2018, 44, 925–928. [CrossRef] [PubMed]
26. Garnacho-Montero, J.; Garcia-Garmendia, J.L.; Barrero-Almodovar, A.; Jimenez-Jimenez, F.J.;
Perez-Paredes, C.; Ortiz-Leyba, C. Impact of adequate empirical antibiotic therapy on the outcome of
patients admitted to the intensive care unit with sepsis. Crit. Care Med. 2003, 31, 2742–2751. [CrossRef]
[PubMed]
27. Harbarth, S.; Garbino, J.; Pugin, J.; Romand, J.A.; Lew, D.; Pittet, D. Inappropriate initial antimicrobial
therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. Am. J.
Med. 2003, 115, 529–535. [CrossRef] [PubMed]
28. Morgan, M.P.; Szakmany, T.; Power, S.G.; Olaniyi, P.; Hall, J.E.; Rowan, K.; Eberl, M. Sepsis Patients with
First and Second-Hit Infections Show Different Outcomes Depending on the Causative Organism. Front.
Microbiol. 2016, 7, 207. [CrossRef] [PubMed]
29. Gao, H.; Evans, T.W.; Finney, S.J. Bench-to-bedside review: Sepsis, severe sepsis and septic shock-does the
nature of the infecting organism matter? Crit. Care. 2008, 12, 213. [CrossRef] [PubMed]
30. Loonen, A.J.M.; Wolffs, P.F.G.; Bruggeman, C.A.; van den Brule, A.J.C. Developments for improved diagnosis
of bacterial bloodstream infections. Eur. J. Clin. Microbiol. Infect. Dis. 2014, 33, 1687–1702. [CrossRef]
31. Heginbothom, M.; Howe, R.; McArtney, B.; Parry-Jones, J.; Smithies, M.; Szakmany, T. The Microbiology of
Severe Sepsis; Public Health Wales: Cardiff, UK, 2013. Available online: http://www.wales.nhs.uk/sites3/page.
cfm?orgId=457&pid=289062013 (accessed on 2 July 2019).
32. Jamal, W.; Tamaray, G.; Pazhoor, A.; Rotimi, V.O. Comparative Evaluation of BacT/ALERT 3D and BACTEC
Systems for the Recovery of Pathogens Causing Bloodstream Infections. Med. Princ. Pract. 2006, 15, 223–227.
[CrossRef]
33. Angus, D.C.; Linde-Zwirble, W.T.; Lidicker, J.; Clermont, G.; Carcillo, J.; Pinsky, M.R. Epidemiology of severe
sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit. Care Med.
2001, 29, 1303–1310. [CrossRef] [PubMed]
34. Churpek, M.M.; Snyder, A.; Han, X.; Sokol, S.; Pettit, N.; Howell, M.D.; Edelson, D.P. Quick Sepsis-related
Organ Failure Assessment, Systemic Inflammatory Response Syndrome, and Early Warning Scores for
Detecting Clinical Deterioration in Infected Patients outside the Intensive Care Unit. Am. J. Respir. Crit. Care
Med. 2017, 195, 906–911. [CrossRef] [PubMed]
35. Keep, J.W.; Messmer, A.S.; Sladden, R.; Burrell, N.; Pinate, R.; Tunnicliff, M.; Glucksman, E. National early
warning score at Emergency Department triage may allow earlier identification of patients with severe sepsis
and septic shock: A retrospective observational study. Emerg. Med. J. 2016, 33, 37–41. [CrossRef] [PubMed]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
